soul trial oral semaglutide cardiovascular outcomes nejm 2025 results 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM NEJM Editorial Fellow Harleen Marwah,

Covering the drugs permanently would require a change in federal law or at least agreement among private health insurers to provide the medications in Part D plans

Butz and his entire staff made the experience seamless from start to finish

That window lines up peak plasma levels with active fat burning

However, bringing prescription medications across the border without valid Canadian prescriptions carries legal risks and is generally not advisable

Weight loss varies, but clinical studies show 1020 lbs lost in 24 months, with 13 lbs per week average

It tends to suit readers who want convenient virtual access to a GLP-1 prescription with clinical oversight and ongoing follow-up, and who are comfortable with a cash-pay model